Efficacy

Traditionally, PASI 75 has been the benchmark to measure treatment success in plaque psoriasis.1

Complete clearance – PASI 100 – is associated with more clinically meaningful benefits to patients’ HRQoL than PASI 75.2

PASI responses with Kyntheum® at 12 weeks vs. ustekinumab3,4

PASI 75, 90 and 100 responses at week 123,4

PASI 75, 90 and 100 responses at week 12 bar graph

Adapted from Supplement to Lebwohl M, et al. 20153 and Lebwohl M, et al. 2015.4 Table 2.

*p-values were calculated by means of Bonferroni-based recycling testing, a multiple testing procedure, at a significance level of 0.05. In the AMAGINE-2 study, on the basis of this sequential testing procedure p=0.08; however, the nominal p-value was significant (p<0.001).3,4

Experience with Kyntheum®

Clearance rates with Kyntheum® were sustained through to two years5

PASI 75, 90 and 100 responses in patients who received Kyntheum® 210mg during the long-term extension5

PASI 75, 90 and 100 responses at week 12 line graph

Adapted from Puig L, et al. 2020.5 Figure 1B.
P values not available in source data.

Kyntheum® efficacy was unaffected by previous biologic use6

The beneficial effect of Kyntheum® on PASI 100 at week 12 vs ustekinumab was maintained regardless of whether:

Patients were biologic naïve or experienced.6

Previous biologic treatment had been successful or unsuccessful.6

Pooled analysis at week 12 of PASI 100 responses
in AMAGINE-2 and AMAGINE-36

Pooled analysis at week 12 of PASI 100 responses bar graph

Adapted from Papp KA et al. 2018.6 Figure 2.

Dermatologists share their experiences with Kyntheum®

Clinical experience
with Kyntheum®

Patient experience
with Kyntheum®

Converting patients
to Kyntheum®

The views and opinions expressed in the films are not claimed to represent the typical patient response to Kyntheum® – individual response and experience may vary from patient to patient.

Return to the product page

HRQoL=Health Related Quality of Life; PASI=Psoriasis Area and Severity Index.

  1. Mrovietz U, et al. Arch Dermatol Res 2011;303:1–10.
  2. Strober B, et al. J Am Acad Dermatol 2016;75:77–81.
  3. Supplement to: Lebwohl M, et al. N Engl J Med 2015;373:1318–28.
  4. Lebwohl M, et al. N Engl J Med 2015;373:1318–28.
  5. Puig L, et al. J Am Acad Dermatol 2020; 82: 352-9.
  6. Papp KA, et al. Br J Dermatol 2018;179(2):320–328.
MAT-42322 Jan 2021